Podcast
Questions and Answers
What is the main advantage of subcutaneous (SC) administration over intravenous (IV) administration?
What is the main advantage of subcutaneous (SC) administration over intravenous (IV) administration?
- Reduced risk of bloodstream infection (correct)
- Faster and complete absorption
- Lower healthcare costs
- Less pharmaceutical preparation required
Why does subcutaneous (SC) administration allow smaller dose size?
Why does subcutaneous (SC) administration allow smaller dose size?
- Reduced risk of necrosis
- Complete absorption into the bloodstream
- Avoidance of first pass metabolism (correct)
- Faster injection process
What is a significant disadvantage of subcutaneous (SC) administration?
What is a significant disadvantage of subcutaneous (SC) administration?
- Risk of local tissue reactions/hypersensitivity (correct)
- Higher patient compliance
- Need for a hospital setting
- Rapid and complete absorption
Why is subcutaneous (SC) administration considered more convenient for patients and medical staff?
Why is subcutaneous (SC) administration considered more convenient for patients and medical staff?
How does subcutaneous (SC) administration contribute to reducing costs for the healthcare system?
How does subcutaneous (SC) administration contribute to reducing costs for the healthcare system?
What is the driving force for interstitial flow in the absorption pathway of the subcutaneous route?
What is the driving force for interstitial flow in the absorption pathway of the subcutaneous route?
In convective transport in the absorption pathway for small peptides and proteins administered subcutaneously, what is NOT a limiting factor for molecular size?
In convective transport in the absorption pathway for small peptides and proteins administered subcutaneously, what is NOT a limiting factor for molecular size?
Why is subcutaneous administration frequently considered more immunogenic than intravenous administration?
Why is subcutaneous administration frequently considered more immunogenic than intravenous administration?
What is a potential limitation of subcutaneous route for peptide/protein therapeutics related to bioavailability?
What is a potential limitation of subcutaneous route for peptide/protein therapeutics related to bioavailability?
Why may the immunogenicity of biologics after subcutaneous administration decrease compared with intradermal administration?
Why may the immunogenicity of biologics after subcutaneous administration decrease compared with intradermal administration?
Flashcards are hidden until you start studying
